Plain-English translation of NCT06749457 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to see if it can help prevent serious bacterial infections in people with end-stage kidney disease who need hemodialysis. Researchers want to understand how safe the medication is and how the body processes it. The study has two phases: first, healthy volunteers will receive a single dose to check for safety, and then people with kidney disease on dialysis will receive two doses spaced three months apart.
People on hemodialysis through central venous catheters face a high risk of serious bacterial infections that can be life-threatening. This medication is being developed as a way to prevent these infections before they start, rather than only treating them after they occur.
If you're in the first phase, you'll have a screening visit, then receive a single intravenous infusion on Day 1, and return for follow-up visits over 12 months. If you're in the second phase (for dialysis patients), you'll have a screening visit, receive two intravenous infusions three months apart, and continue follow-up visits for 12 months after your last dose. All participants will have blood tests and physical exams to monitor their safety.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States